References

aids

ВИЧ-инфекция и иммуносупрессии

HIV Infection and Immunosuppressive Disorders

2077-9828

Baltic Medical Education Center

10.22328/2077-9828-2020-12-4-7-22

aids-578

Research Article

РЕДАКЦИОННАЯ СТАТЬЯ

EDITORIAL

Иммунопатогенез и перспективы иммунотерапии коронавирусной инфекции

Immunopathogenesis and perspectives for immunotherapy of coronavirus infection

https://orcid.org/0000-0001-6779-7761

Симбирцев

А. С.

Simbirtsev

A. S.

Симбирцев Андрей Семенович — доктор медицинских наук, профессор, член-корреспондент Российской академии наук, главный научный сотрудник

197110, Санкт-Петербург, Пудожская ул., д. 7

Andrey S. Simbirtsev

St. Petersburg

a.s.simbirtsev@hpb.spb.ru

Государственный научно-исследовательский институт особо чистых биопрепаратов Федерального медико-биологического агентстваРоссияState research institute of highly pure biopreparationsRussian Federation

2020

08022021

124722

2021

Симбирцев А.С.

Simbirtsev A.S.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://hiv.bmoc-spb.ru/jour/article/view/578

Инфицирование высокопатогенным коронавирусом SARS-CoV-2 в ряде случаев приводит к развитию тяжелого вирусного заболевания (COVID-19), иногда со смертельным исходом. Иммунопатогенез COVID-19 связан с развитием несбалансированного иммунного ответа на вирус с недостаточным синтезом интерферона в начале заболевания, но с последующей гиперпродукцией провоспалительных цитокинов, служащей причиной неадекватно сильного воспаления в легочной ткани с развитием острого поражения легких и респираторного дистресс-синдрома. Перспективными направлениями иммунотерапии COVID-19 могут быть: лечение препаратами интраназального рекомбинантного интерферона в начальной стадии инфекционного процесса, применение антицитокиновой терапии при развитии тяжелой пневмонии и цитокинового шторма, пассивная иммунизация с использование плазмы крови переболевших пациентов и препаратов терапевтических моноклональных антител, профилактическая вакцинация.

Highly pathogenic coronavirus SARS-CoV-2 is the cause of COVID-19 in humans sometimes with severe clinical manifestations and death. COVID-19 immunopathogenesis is linked with dysregulated immune response with decreased interferon synthesis at the beginning of infection followed by inﬂammatory cytokines hyperproduction, resulting in an exuberant lung inﬂammation and respiratory distress syndrome. Perspective immunotherapy directions for COVID-19 could be: intranasal recombinant interferon application in the initial stage of disease, anticytokine therapy at the stage of severe pneumonia and cytokine storm development, passive immunization with blood plasma of recovered patients or therapeutic monoclonal antibodies, prophylactic vaccination.

иммунопатогенез коронавирусной инфекцииинтерферонцитокиновый штормлегочное воспалениеиммунотерапия COVID-19

coronavirus infection immunopathogenesisinterferoncytokine stormlung inflammationCOVID-19 immunotherapy

References1

Wu F., Zhao S., Yu B., Chen Y.M., Wang W., Song Z.G. A new coronavirus associated with human respiratory disease in China // Nature. 2020. Vol. 579 (7798). P. 265–269. doi: 10.1038/s41586-020-2008-3.

Chen N., Zhou M., Dong X. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study // Lancet. 2020. Vol. 395 (10223). P. 507–513. doi: 10.1016/S0140-6736(20)30211-7.

Huang C., Wang Y., Li X. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China // Lancet. 2020. Vol. 395 (10223). P. 497–506. doi: 10.1016/S0140-6736(20)30183-5.

Xu Z., Shi L., Wang Y. et al. Pathological ﬁndings of COVID-19 associated with acute respiratory distress syndrome // Lancet Respir. Med. 2020. Vol. 8 (4). P. 420–422. doi: 10.1016/S2213-2600(20)30076-X.

Ou X., Liu Y., Lei X. et al. Characterization of Spike Glycoprotein of SARS-CoV-2 on Virus Entry and Its Immune Cross-Reactivity With SARSCoV // Nat. Commun. 2020. Vol. 11 (1). P. 1620. doi: 10.1038/s41467-020-15562-9.

Zhou P., Yang X., Wang X. A pneumonia outbreak associated with a new coronavirus of probable bat origin // Nature. 2020. Vol. 579 (7798). P. 270–273. doi: 10.1038/s41586-020-2012-7.

Ulrich H., Pillat M. CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement // Stem Cell Rev Rep. 2020. Apr. 20. doi: 10.1007/s12015-020-09976-7. Online ahead of print.

Wang Q., Zhang Y., Wu L. Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2 // Cell. 2020. Vol. 181. P. 1–11. https://doi.org/10.1016/j.cell.2020.03.045

Takeuchi O., Akira S. Pattern recognition receptors and inﬂammation // Cell. 2010. Vol. 140 (6). P. 805–820. doi: 10.1016/j.cell.2010.01.022.

Jefferies C. Regulating IRFs in IFN Driven Disease // Front. Immunol. 2019. Vol. 10. P. 325. doi: 10.3389/ﬁmmu.2019.00325.

Mitchell S., Mercado E., Adelaja A. An NFkB Activity Calculator to Delineate Signaling Crosstalk: Type I and II Interferons Enhance NFkB via Distinct Mechanisms // Front. Immunol. 2019. Vol. 10. P. 1425. doi: 10.3389/ﬁmmu.2019.01425.

Zhu X., Wang Y., Zhang H. Genetic variation of the human alpha-2-Heremans-Schmid glycoprotein (AHSG) gene associated with the risk of SARS-CoV infection // PloS One. 2011. Vol. 6 (8). P. e23730. doi: 10.1371/journal.pone.0023730.

Ivashkiv L., Donlin L. Regulation of type I interferon responses // Nature reviews Immunology. 2014. Vol. 14 (1). P. 36–49. doi: 10.1038/nri3581.

Pestka S., Krause C., Walter M. Interferons, interferon-like cytokines, and their receptors // Immunol. Rev. 2004. Vol. 202. P. 8–32. doi: 10.1111/j.0105-2896.2004.00204.x.

Kotenko S., Gallagher G., Baurin V. IFN lambdas mediate antiviral protection through a distinct class II cytokine receptor complex // Nat. Immunol. 2003. Vol. 4 (1). P. 69–77. doi: 10.1038/ni875.

Prejean C., Colamonici O. Role of the cytoplasmic domains of the type I interferon receptor subunits in signaling // Seminars in Cancer Biology. 2000. Vol. 10 (2). P. 83–92. doi: 10.1006/scbi.2000.0311.

Schoggins J., Wilson S., Panis M. A diverse range of gene products are effectors of the type I interferon antiviral response // Nature. 2011. Vol. 472 (7344). P. 481–485. doi: 10.1038/nature09907.

Ye L., Schnepf D., Staeheli P. Interferon- l orchestrates innate and adaptive mucosal immune responses // Nat. Rev. Immunol. 2019. Vol. 19 (10). P. 614–625. doi: 10.1038/s41577-019-0182-z.

Fairman P., Angel J. The effect of human immunodeﬁciency virus-1 on monocyte-derived dendritic cell maturation and function // Clinical and experimental immunology. 2012. Vol. 170 (1). P. 101–113. doi: 10.1111/j.1365-2249.2012.04628.x.

Cardone M., Ikeda K., Varano B., Gessani S., Conti L. HIV-1-induced impairment of dendritic cell cross talk with gammadelta T lymphocytes // Journal of virology. 2015. Vol. 89 (9). P. 4798–4808. doi: 10.1128/JVI.03681-14.

Shokri S., Mahmoudvand S., Taherkhani R., Farshadpour F. Modulation of the immune response by Middle East respiratory syndrome coronavirus // J. Cell. Physiol. 2019. Vol. 234 (3). P. 2143–2151. doi: 10.1002/jcp.27155.

Schulz K., Mossman K. Viral Evasion Strategies in Type I IFN Signaling — A Summary of Recent Developments // Front. Immunol. 2016. Vol. 7. P. 498. doi: 10.3389/ﬁmmu.2016.00498.

Spiegel M., Pichlmair A., Martinez-Sobrido L. et al. Inhibition of Beta interferon induction by severe acute respiratory syndrome coronavirus suggests a two-step model for activation of interferon regulatory factor 3 // Journal of virology. 2005. Vol. 79 (4). P. 2079–2086. doi: 10.1128/JVI.79.4.2079-2086.2005.

Kopecky-Bromberg S., Martinez-Sobrido L., Frieman M., Baric R., Palese P. Severe acute respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 6, and nucleocapsid proteins function as interferon antagonists // Journal of virology. 2007. Vol. 81 (2). P. 548–557. doi: 10.1128/JVI.01782-06.

Lu X., Pan J., Tao J., Guo D. SARS-CoV nucleocapsid protein antagonizes IFN-beta response by targeting initial step of IFN-beta induction pathway, and its C-terminal region is critical for the antagonism // Virus genes. 2011. Vol. 42 (1). P. 37–45. doi: 10.1007/s11262-010-0544-x.

Kindler E., Thiel V., Weber F. Interaction of SARS and MERS Coronaviruses with the Antiviral Interferon Response // Adv. Virus Res. 2016. Vol. 96. P. 219–243. doi: 10.1016/bs.aivir.2016.08.006.

de Wit E., van Doremalen N., Falzarano D., Munster V. SARS and MERS: recent insights into emerging coronaviruses // Nat. Rev. Microbiol. 2016. Vol. 14 (8). P. 523–534. doi: 10.1038/nrmicro.2016.81.

Kikkert M. Innate Immune Evasion by Human Respiratory RNA Viruses // J. Innate Immun. 2020. Vol. 12 (1). P. 4–20. doi: 10.1159/000503030.

Faure E., Poissy J., Goffard A. Distinct immune response in two MERS-CoV-infected patients: can we go from bench to bedside? // PLoS One. 2014. Vol. 9 (2). e88716. doi: 10.1371/journal.pone.0088716.

Channappanavar R., Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology // Semin Immunopathol. 2017. Vol. 39 (5). P. 529–539. doi: 10.1007/s00281-017-0629-x.

Lessler J., Reich N., Brookmeyer R. Incubation periods of acute respiratory viral infections: a systematic review // Lancet Infect. Dis. 2009. Vol. 9 (5). P. 291–300. doi: 10.1016/S1473-3099(09)70069-6.

Channappanavar R., Fett C., Zhao J., Meyerholz D., Perlman S. Virus-speciﬁc memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection // J. Virol. 2014. Vol. 88 (19). P. 11034–11044. doi: 10.1128/JVI.01505-14.

Zhao J., Li K., Wohlford-Lenane C. et al. Rapid generation of a mouse model for Middle East respiratory syndrome // Proc. Natl. Acad. Sci. USA. 2014. Vol. 111 (13). P. 4970–4975. doi: 10.1073/pnas.1323279111.

Maloir Q., Ghysen K., von Frenckell C., Louis R., Guiot J. [Acute respiratory distress revealing antisynthetase syndrome] // Revue medicale de Liege. 2018. Vol. 73 (7–8). P. 370–375. PMID: 30113776.

Yang Y., Xiong Z., Zhang S. Bcl-xL inhibits T-cell apoptosis induced by expression of SARS coronavirus E protein in the absence of growth factors // Biochem. J. 2005. Vol. 392 (Pt 1). P. 135–143. doi: 10.1042/BJ20050698.

Mubarak A., Alturaiki W., Hemida M. Middle East Respiratory Syndrome Coronavirus (MERS-CoV): Infection, Immunological Response, and Vaccine Development // J. Immunol. Res. 2019. Vol. 2019. P. 6491738. doi: 10.1155/2019/6491738.

Chen J., Lau Y., Lamirande E. Cellular immune responses to severe acute respiratory syndrome coronavirus (SARS-CoV) infection in senescent BALB/c mice: CD4+ T cells are important in control of SARS-CoV infection // J. Virol. 2010. Vol. 84 (3). P. 1289–1301. doi: 10.1128/JVI.01281-09.

Li C., Wu H., Yan H. T cell responses to whole SARS coronavirus in humans // J. Immunol. 2008. Vol. 181 (8). P. 5490–5500. doi: 10.4049/jimmunol.181.8.5490.

Liu W., Fontanet A., Zhang P. Two-year prospective study of the humoral immune response of patients with severe acute respiratory syndrome // J. Infect. Dis. 2006. Vol. 193 (6). P. 792–795. doi: 10.1086/500469.

Niu P., Zhang S., Zhou P. Ultrapotent Human Neutralizing Antibody Repertoires Against Middle East Respiratory Syndrome Coronavirus From a Recovered Patient // J. Infect. Dis. 2018. Vol. 218 (8). P. 1249–1260. doi: 10.1093/infdis/jiy311.

Liu W., Zhao M., Liu K. T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV // Antiviral Res. 2017. Vol. 137. P. 82–92. doi: 10.1016/j.antiviral.2016.11.006.

Thevarajan I., Nguyen T., Koutsakos M. Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19 // Nat. Med. 2020. Vol. 26. P. 453–455. https://doi.org/10.1038/s41591-020-0819-2.

Zhao J., Yuan Q., Wang H. Antibody responses to SARS- CoV-2 in patients of novel coronavirus disease 2019 // Clin. Infect. Dis. 2020. Mar. 28. ciaa344. doi: 10.1093/cid/ciaa344. Online ahead of print.

Huang K., Su I.-J., Theron M. An interferon-gamma-related cytokine storm in SARS patients // J. Med. Virol. 2005. Vol. 75 (2). P. 185–194. doi: 10.1002/jmv.20255.

Qin C., Zhou L., Hu Z. et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China // Clin. Infect. Dis. 2020. Mar. 12. ciaa248. doi: 10.1093/cid/ciaa248.

Wong C., Lam C., Wu A. et al. Plasma inﬂammatory cytokines and chemokines in severe acute respiratory syndrome // Clin. Exp. Immunol. 2004. Vol. 136 (1). P. 95–103 doi: 10.1111/j.1365-2249.2004.02415.x.

Mahallawi W., Khabour O., Zhang Q., Makhdoum H., Suliman B. MERS-CoV infection in humans is associated with a pro-inﬂammatory Th1 and Th17 cytokine proﬁle // Cytokine. 2018. Vol. 104. P. 8–13. doi: 10.1016/j.cyto.2018.01.025.

Nicholls J., Poon L., Lee K. Lung pathology of fatal severe acute respiratory syndrome // Lancet. 2003. Vol. 361 (9371). P. 1773–1778. doi: 10.1016/S0140-6736(03)13413-7.

Gu J., Gong E., Zhang B. et al. Multiple organ infection and the pathogenesis of SARS // J. Exp. Med. 2005. Vol. 202 (3). P. 415–424. doi: 10.1084/jem.20050828.

Li T., Qiu Z., Zhang L. et al. Signiﬁcant changes of peripheral T lymphocyte subsets in patients with severe acute respiratory syndrome // J. Infect. Dis. 2004. Vol. 189 (4). P. 648–651. doi: 10.1086/381535.

Channappanavar R., Fehr A., Vijay R. Dysregulated type I interferon and inﬂammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice // Cell Host Microbe. 2016. Vol. 19 (2). P. 181–193. doi: 10.1016/j.chom.2016.01.007.

Cameron M., Xu L., Danesh A. Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome // J. Virol. 2007. Vol. 81 (16). P. 8692–8706. doi: 10.1128/JVI.00527-07.

Smits S., Lang A., van den Brand J. et al. Exacerbated innate host response to SARS-CoV in aged non-human primates // PLoS Pathog. 2010. Vol. 6 (2). e1000756. doi: 10.1371/journal.ppat.1000756.

Rockx B., Baas T., Zornetzer G. et al. Early upregulation of acute respiratory distress syndrome-associated cytokines promotes lethal disease in an aged-mouse model of severe acute respiratory syndrome coronavirus infection // J. Virol. 2009. Vol. 83 (14). P. 7062–7074. doi: 10.1128/JVI.00127-09.

Wong J., Viswanathan S., Wang M. Current and future developments in the treatment of virus-induced hypercytokinemia // Future Med. Chem. 2017. Vol. 9 (2). P. 169–178. doi: 10.4155/fmc-2016-0181.

Teijaro J., Walsh K., Rice S. Mapping the innate cascade essential for cytokine storm during inﬂuenza virus infection // Proc. Natl. Acad. Sci. USA. 2014. Vol. 111 (10). P. 3799–3804. doi: 10.1073/pnas.1400593111.

Gao R., Bhatnagar J., Blau D. et al. Cytokine and chemokine proﬁles in lung tissues from fatal cases of 2009 pandemic inﬂuenza A (H1N1): role of the host immune response in pathogenesis // Am. J. Pathol. 2013. Vol. 183 (4). P. 1258–1268. doi: 10.1016/j.ajpath.2013.06.023.

Thomas M., Mani R., Philip M. Proinﬂammatory chemokines are major mediators of exuberant immune response associated with inﬂuenza A (H1N1) pdm09 virus infection // J. Med. Virol. 2017. Vol. 89 (8). P. 1373–1381. doi: 10.1002/jmv.24781.

Betáková T., Kostrabova A., Lachova V., Turianova L. Cytokines induced during inﬂuenza virus infection // Curr. Pharm. Des. 2017. Vol. 23 (18). P. 2616–2622. doi: 10.2174/1381612823666170316123736.

To K., Hung I., Li I. et al. Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 inﬂuenza virus infection // Clin. Infect. Dis. 2010. Vol. 50 (6). P. 850–859. doi: 10.1086/650581.

Hayden F., Fritz R., Lobo M. Local and systemic cytokine responses during experimental human inﬂuenza A virus infection. Relation to symptom formation and host defense // J. Clin. Invest. 1998. Vol. 101 (3). P. 643–649. doi: 10.1172/JCI1355.

Yu L., Wang Z., Chen Y. Clinical, virological, and histopathological manifestations of fatal human infections by avian inﬂuenza A(H7N9) virus // Clin. Infect. Dis. 2013. Vol. 57 (10). P. 1449–1457. doi: 10.1093/cid/cit541.

Bohmwald K., Gálvez N., Canedo-Marroquín G. Contribution of Cytokines to Tissue Damage During Human Respiratory Syncytial Virus Infection // Front Immunol. 2019. Vol. 10. P. 452. doi: 10.3389/ﬁmmu.2019.00452.

Zhao J., Yang Y., Huang H. Relationship between the ABO Blood Group and the COVID-19 Susceptibility // MedRxiv 2020.03.11.20031096. doi: 10.1101/2020.03.11.20031096.

Liu W., Li H. COVID-19: Attacks the 1-Beta Chain of Hemoglobin and Captures the Porphyrin to Inhibit Human Heme Metabolism // Chem. Rxiv. 2020. Preprint. doi: 10.26434/chemrxiv.11938173.v6.

Zhang L, Liu Y. Potential interventions for novel coronavirus in China: a systemic review // J. Med. Virol. 2020. Vol. 92 (5). P. 479–490. doi: 10.1002/jmv.25707.

De Clercq E., Li G. Approved antiviral drugs over the past 50 years // Clin. Microbiol. Rev. 2016. Vol. 29 (3). P. 695–747. doi: 10.1128/CMR.00102-15.

Zumla A., Rao M., Wallis R.S. Host-directed therapies for infectious diseases: current status, recent progress, and future prospects // Lancet. 2016. Vol. 16 (4). e47–63. doi: 10.1016/S1473-3099(16)00078-5.

Kaufmann S., Dorhoi A., Hotchkiss R., Bartenschlager R. Host-directed therapies for bacterial and viral infections // Nat. Rev. Drug. Disc. 2018. Vol. 17 (1). P. 35–56. doi: 10.1038/nrd.2017.162.

Falzarano D., de Witt E., Rasmussen A. et al. Treatment with interferon-alpha2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques // Nat. Med. 2013. Vol. 19 (10). P. 1313–1317. doi: 10.1038/nm.3362.

Дерябин П.Г., Зарубаев В.В. К вопросу о коронавирусной инфекции и перспективах профилактики и лечения препаратами интерферона альфа-2b человеческого рекомбинантного // Инфекционные болезни. 2014. Т. 12, № 3. С. 32–34.

Deryabin P.G., Zarubaev V.V. Regarding the Coronavirus infection and prospects for prevention and treatment by recombinant human interferon alpha-2b medications. Infectious diseases, 2014, Vol. 12 (30), pp. 32–34 (In Russ.).

Tyrrell D. The efficacy and tolerance of intranasal interferons: studies at the Common Cold Unit // J. Antimicrob. Chemother. 1986. Vol. 18, Suppl B. P. 153–156. doi: 10.1093/jac/18.supplement_b.153.

Omrani A., Saad M., Baig K. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study // Lancet Infect Dis. 2014. Vol. 14 (11). P. 1090–1095. doi: 10.1016/S1473-3099(14)70920-X.

Zumla A., Chan J., Azhar E. Coronaviruses — drug discovery and therapeutic options // Nat. Rev. Drug Discov. 2016. Vol. 15 (5). P. 327–347 doi: 10.1038/nrd.2015.37.

Dong L., Hu S., Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19) // Drug Discoveries & Therapeutics. 2020. Vol. 14 (1). P. 58–60. doi: 10.5582/ddt.2020.01012.

Mair-Jenkins J., Saavedra-Campos M., Baillie J. et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis // J. Infect. Dis. 2015. Vol. 211 (1). P. 80–90. doi: 10.1093/infdis/jiu396.

Shanmugaraj B., Siriwattananon K., Wangkanont K., Phoolcharoen W. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19) // Asian. Pac. J. Allergy Immunol. 2020. Vol. 38 (1). P. 10–18. doi: 10.12932/AP-200220-0773.

Coughlin M., Prabhakar B. Neutralizing human monoclonal antibodies to Severe acute respiratory syndrome coronavirus: target, mechanism of action and therapeutic potential // Rev. Med. Virol. 2012. Vol. 22 (1). P. 2–17. doi: 10.1002/rmv.706.

Niu P., Zhao G., Deng Y. A novel human mAb (MERS-GD27) provides prophylactic and postexposure efficacy in MERS-CoV susceptible mice // Science China Life sciences. 2018. Vol. 61 (10). P. 1280–1282. doi: 10.1007/s11427-018-9343-8.

Ying T., Du L., Ju T. Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies // J. Virol. 2014. Vol. 88 (14). P. 7796–7805. doi: 10.1128/JVI.00912-14.

Houser K., Gretebeck L., Ying T. et al. Prophylaxis With a Middle East Respiratory Syndrome Coronavirus (MERS-CoV)-Speciﬁc Human Monoclonal Antibody Protects Rabbits From MERS-CoV Infection // J. Infect. Dis. 2016. Vol. 213 (10). P. 1557–1561. doi: 10.1093/infdis/jiw080.

van Doremalen N., Falzarano D., Ying T. Efficacy of antibody-based therapies against Middle East respiratory syndrome coronavirus (MERSCoV) in common marmosets // Antiviral Res. 2017. Vol. 143. P. 30–37. doi: 10.1016/j.antiviral.2017.03.025.

Ahmed S., Quadeer A., McKay M. Preliminary Identiﬁcation of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies // Viruses. 2020. Vol. 12 (3). P. 254. doi: 10.3390/v12030254.

Prompetchara E., Ketloy C., Palaga T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic // Asian Pac. J. Allergy Immunol. 2020. Vol. 38 (1). P. 1–9. doi: 10.12932/AP-200220-0772.

Du L., He Y., Zhou Y. et al. The spike protein of SARS-CoV — a target for vaccine and therapeutic development // Nat. Rev. Microbiol. 2009. Vol. 7 (3). Р. 226–236. doi: 10.1038/nrmicro2090.

Al-Amri S., Abbas A., Siddiq L. et al. Immunogenicity of Candidate MERS-CoV DNA Vaccines Based on the Spike Protein // Sci Rep. 2017. Vol. 7. P. 44875. doi: 10.1038/srep44875.

Ng O., Chia A., Tan A. Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection // Vaccine. 2016. Vol. 34 (17). P. 2008–2014. doi: 10.1016/j.vaccine.2016.02.063.

The authors declare that there are no conflicts of interest present.